MoneyShow: InMode is More than Cosmetic Gains
MoneyShow: InMode is More than Cosmetic Gains
Tom Bishop, small-cap expert and editor of BI Research, writes that “minimally invasive cosmetic products put InMode’s technology in the catbird seat post-pandemic. It’s products not requiring hospitalization or anesthesia or lengthy recovery time — or in some cases — even much face-to-face time with physicians. This is especially true for the newly introduced Evoke and Evolve, hands-free face and remodeling platforms. InMode is in an extraordinarily strong financial position to easily weather this storm and prosper on pent up demand and new products on the other side. Think a year out; the stock is a “Strong Buy”.
